disappointed Steve. my Q&A in and for you, remain expecting this, begin are very morning then I in four also the period. trends of by you we what weeks ago. some differed from analysis and we these optimistic sugarcoat full community about during our any may describing remarks expected. we for explanation deliver I for third are positive there this third quarter what that investment two in about course of quarter results. will for have and areas some which any growth conclude did We environment providing won't we of with three Thank current our comment comments are our my guidance quarter on by investors pre-announced longer our four will term. outlook this the I were our context results our results not our the very answer will quarter said give a of each short accept that these accountability the you questions I'll and prospects. There of our the
Harvey. Irma The to and lesser results expectations from first between our Hurricane difference resulted and a Hurricane extent
our plans these we not these our more outstanding disasters. Fort directly impacted by much could and prepare an there's continuity were did facilities and hurricanes, have business job. We for done to Houston team Our executed Myers both
these disruptions which and closures our at extremely the natural of experienced In in fact managed any all. significant opinion was and felt though systems in barely we I'm our plus through lab my manner people clients A impact proud Even disasters. it performance. an our had teams
quarter. has difference a adjusted do slightly Path for with to impact positive but the revenue divesture on divestiture EBITDA had our second this The Logic, reduced of
attempting many employees company of As protected We strategically a you to and now a Path Path profitable Without been know and going the financially focused and forward. have as while more our because more Path as was Logic's or which be it on possible struck Logic clients to we we incurred additive sale. our loss is deal will divest Logic business. a no longer for
QNS. million The or expectations for excuse quantity revenue recorded we reflected was I this, for the the sufficient no reason adjustment. third is investor because was result not There revenue certain $X.X missed mean adjustment were tests
Although not these tests zero unless reported we we in QNS out result revenue. test partial are results QNS testing full generally expense incurred QNS do specimens of the bill for and
have We controls situation recur. and ensure does this procedures to that enhanced established not accounting
In revenue and the to to addition higher profitability slightly going than should the reduced that the a and many for is they're deny we insurance reason missed our had an have secured get less be test lab, test for as higher give Unfortunately care are dynamics as improve will In organizations increasingly the implemented the result the the payers we new required of well pre-authorized our testing using not boost of the by in preauthorization performance allow be test. efforts to and QNS order changing refuse expectations entire billing refusing of pre-authorization bad expense was of during performed recently claim. requiring pay the will of than tests. and often molecular because for pay forward. fourth physician This investor technologies sample tissue ordering be patient paid. to must included despite a if integration. lab payer much and instances rather an Medicare as The number sometimes companies a by best Managed and operation debt companies final advance expected our value the insurance more to Medicare care frequently to Clarient
panels. denied for increasingly payment specific particularly are organizations next generation care multi-gene test based managed and Medicare addition sequencing In molecular disease
guide over Even care, year. by and are these panels decisions though panels valued sometimes us. Medicare in they which these and important are clients past treatment reimburse has Our our care for managed our important patient the and biomarkers to grown payers refused volume test important include significantly
of of managed context is from derived specific revenue. built and total X% these approximately disease care Medicare panels revenue to For
nearly preferable of hospital directly our our directly our Fortunately rules. for what adapting because order. we deal under to This services and fortunately our for are we individual have us challenges enough XX% care and and bills Medicare to for Also pay are a and them. they sent bad new debt prefer expertise scale we with us for bill they with to clients managed contracts much hospitals is situation
the that have of requirements proactively submitted. We in ensure confusion are payers about and systems educating pre-authorization requests sent. establishing communicating the in clients typical when test several our processes documentation and enhanced to algorithms is to our a pre-authorization before ways, secured reduce test the order We're we're new preauthorization chance with is
about an These us process Additionally future. quarter that very sent positive we they our turn those With lab have time some in to attention a fundamentals the understanding trends pre-authorization are even business. that the the to accessioned identify at four let's excited acquisition test laboratories. and fundamental in our three to dynamics a what our of require are approval our have secure is established before to
in and by recent hit quarter growth is our molecular past was to continued market trends of fundamental flow with most XX.X% Moreover FISH. getting our than in our histology in business in reported share those the We services despite strength accelerating two clinical in ability by to continue gain volume the hurricanes. our this our One growth core growth labs positive more and balanced cytometry accompanied division.
taking most and of market. segments force focused again once in winning Our clearly are share new sales is business the on we
in business also services up We quarter with and XX% to number health year also of is signed a of in record division million. XX% our year million. $XX reported demonstrated revenue record new this backlog is a contracts $X.X The up to over pharma
momentum its very the this business excited build remain watching we in are and about prospects. We
despite an very overtime year quarter, need over down, to in our year our clinical a and expectations maintained California and gains due down and initial to it's our directed four this control These surprise more with also also we our having accurate cost We XX% our shortfall expectations test prospects. both guidance Even were disappointed strong the by failed anticipated accommodate business provide staff with long year We a per again in of samples the investors business, increased to than over cost realize consistent with in outstanding were market X% to we disappointment. past and near spike to pharma We right control relative up that significant our growth in the was with and term once continuing well expenses in-line are up year. by and our share our term revenue goals. productivity quarter a strong related continued cost our keep and assessment earnings was able cost to healthy trends as and hurricanes. fundamental
as you over of past this most and the publicly has many of has As traded case know been year. over a Neogenomics met history even the not our expectations, company exceeded
at again look have reduce adopted the our in hard and that forecasting quarters. we a which taken future have establishing prophecies miss for guidance We chances should process and
continued of and both significant pharma division for front. outlook in an by general some reimbursement Our services clinical pressure on the includes expectation offset quarter collections and four commercial our momentum
and momentum. On teams the have win our robust, accounts sales we remains clinical continue side to new our volume growth excellent
FISH annualize cytometry. and in pressure influx greater Despite and four in generation sequencing to We growth strength as next mix last began of expect the in our the traditional such in continued begin more expect flow we year. test also improvements and initial molecular PDL-X reimbursement which of we as quarter stability higher technologies testing on paying expect
multiomyx, of immuno-oncology proprietary Our outlook new very winning backlog. revenue four pharma both We're is for division technology used terms and for contracts for immunohistochemistry primarily quarter in the testing our positive and testing. services
In the in this and this addition services margin to our quarter expect benefit more gains of as to XX% continue improve above was scale. this pharma we past gross business
expect cost in the of test implemented see to initiatives and past continued several months. result per new we scale cost over reductions as a increased side On the
$XX in levels $XX we continue to dynamics the million $X to adapt to our going that to to remain perspective. will of four million about these elevated as to EBITDA I'm quarter. million the revenue quarter expect result in we changes longer-term position at to of adjusted competitive expect fourth and talk Overall, $XX now transition environment. payer We in debt million in bad and
everyone that we by environment. navigating pretty start challenging track have a me a Let record in reminding successful
XX over cumbersome Medicare calls, years, and regulatory I quarters grown in XX the faced times. in have our changes the Nevertheless, quarterly severe Over volume reimbursement has competition. we by investor which these cuts, intense hosted
times about Our XX has value $XX has how to over to challenges understand million we know grown through $XXX revenue gone them. by do over from our and manage do and We enterprise million.
challenges win. and managed capabilities our general, NeoGenomics Medicare us we care reimbursement and to practices these deal to present for industry continues with and in Although to the have believe for
competitive than our position been. fact, better In is ever it's
We and cutting retracting back service respond and stories on and have Every service on scale, At taking great we're time, balance hear to off market. care, share. ability of market and competitors stores react we patient quality or quickly the and people, the week in laying the focus, relentlessly same focused effectively. sales
intend We to believe that. in is positioned gain expect We advantage that relative to this fully competitive trend continue NeoGenomics to and environment do just to we continue.
for of demand continues this oncology increase. the to importantly, testing More medicine area complex exciting precision in
leading oncology growth. our accelerate that service we're demand focused aggressively we to positioned uniquely opportunities meet pursuing full laboratory, the are As to market and
we're with relationships a pursuing. Here We're of organizations. establishing healthcare are opportunities more preferred just that the few national specific
weeks, new largest of oncology In a preferred large the giving us we're we with hospital We've multiple gain contract the of last partnerships working in in one a the also year ability the with entered accounts. fact, forming past more. hospital systems We're relationships X with to add finalized country, and practices. the over organizations number to
uptick cross-sell our We're from and capitalize used the additional in even cytometry past year, us for larger an to see molecular and we continuing exclusively on be dozens includes pipeline traditional work large oncology several for our the menu. reference test to became who of comprehensive FISH, histology. lab our Over once oncology We're accounts. clients practices. tend These flow pathology to beginning to opportunities practices exclusive than
for facility. lab and grand selling Pharma this and Our identify building sales new progress. to they and detailed Services cross November for have our establishing several teams lab this making We're scheduled under at contract have business for of opened We plans opening global Geneva, for is customers a X. opportunities projects the in footprint. are Switzerland already our The request
In fact, grow several confident We more bids profitable a million in ability with to contracted process. business. already $X.X in backlog build our to remain and is our
and to will reiterate goals per practices of new continue IT application We business, and our new Test we're growth. drive Pharma excellent working contribution future. growth our leveraging bullish revenue positioning XX% inevitable Cost system by reductions scale. our automation, steadfastly our I enhancements, believe through of technology, our to plus volume challenges, we in mid-teens increasing summary, XX% financial incremental on business competitive in EBITDA in while our long-term best growth clinical about through revenue remain is In some short-term our and we XX%
slightly to Investor the detail turn Q&A session. in third floor to Now Executive Steve lead a results and over through us Relations going of President we're Jones, more quarter our Vice Director and review to
